Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus Nephritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230000
- Anhui Provincial Hospital
-
-
Beijing
-
Beijing, Beijing, China, 102206
- Peking University International Hospital
-
Beijing, Beijing, China, 100044
- Peking University Peoples Hospital
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- The First Affiliated Hospital of Xiamen University
-
Xiamen, Fujian, China, 361004
- Zhongshan Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong Provincial Peoples Hospital
-
Guangzhou, Guangdong, China, 510000
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital, Sun Yat Sen University
-
Guangzhou, Guangdong, China, 510655
- Guangdong Province Traditional Chinese Medical Hospitsal
-
Guangzhou, Guangdong, China, 510630
- The Third Affiliated Hospital, Sun Yat Sen University
-
Jiangmen, Guangdong, China, 529030
- Jiangmen Central Hospital
-
Shenzhen, Guangdong, China, 518036
- Peking University Shenzhen Hospital
-
Shenzhen, Guangdong, China, 518037
- The Second Peoples Hospital of Shenzhen
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545005
- Liuzhou Workers Hospital
-
Nanning, Guangxi, China, 530021
- The Peoples Hospital of Guangxi Zhuang Autonomous Region
-
-
Guizhou
-
Guiyang, Guizhou, China, 550002
- Guizhou Provincial Peoples Hospital
-
-
Hainan
-
Haikou, Hainan, China, 570206
- Hainan General Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Renmin Hospital of Wuhan University
-
-
Hunan
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China, 210002
- General Hospital of Eastern Theater Command
-
Wuxi, Jiangsu, China, 214023
- Wuxi Peoples Hospital
-
Xuzhou, Jiangsu, China, 221000
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The Second Affiliated Hospital of Nanchang University
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University Branch Donghu
-
-
Jilin
-
Changchun, Jilin, China, 130022
- The Second Hospital of Jilin University
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- First Affiliated Hospital of Dalian Medical University
-
Shenyang, Liaoning, China, 110004
- Shengjing Hospital of China Medical University
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750004
- General Hospital of Ningxia Medical University
-
-
Shaanxi
-
Xian, Shaanxi, China, 710061
- The First Affiliated Hospital of Xian Jiaotong University
-
Xian, Shaanxi, China, 710004
- The Second Affiliated Hospital of Xian Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Shandong Provincial Hospital
-
Qingdao, Shandong, China, 266000
- The Affiliated Hospital of Qingdao University Branch South
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Shanghai General Hospital
-
Shanghai, Shanghai, China, 200040
- Huashan Hospital Affiliated to Fudan University
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030001
- Second Hospital of Shanxi Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, China, 610071
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- The Second Affiliated Hospital of Tianjin Medical University
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830054
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Ningbo, Zhejiang, China, 315010
- Ningbo First Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Clinical diagnosis of SLE according to the Systemic Lupus International Collaborating Clinics 2012 criteria.
- ISN/RPS 2003 Class III/IV lupus nephritis [Type III(A), III (A+C), IV (A), and IV (A+C)], with or without Class V, as confirmed by a renal biopsy.
- Positive antinuclear antibodies, positive anti-dsDNA autoantibody, and/or positive anti Smith autoantibody at screening
- Has 24-hour urine protein excretion > 1.0 g at screening.
Key Exclusion Criteria:
Exclusion criteria related to systemic lupus erythematous and other diseases:
- Glomerulonephritis caused by reasons other than systemic lupus erythematous.
- Sclerosis in >50% of glomeruli on renal biopsy.
- Any other inflammatory diseases that might confound the assessments of efficacy, including but not limited to rheumatoid arthritis, myositis, vasculitis, or overlapping syndrome.
- Severe extrarenal SLE, including but not limited to severe pulmonary arterial hypertension, severe myocarditis, severe central nervous system lupus (such as neuropsychiatric SLE, seizures, psychosis, transverse myelitis, central nervous system vasculitis and optic neuritis), etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Zanubrutinib Low Dose
Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks
|
Administered as specified in the treatment arm
Other Names:
|
|
Experimental: Zanubrutinib High Dose
Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks
|
Administered as specified in the treatment arm
Other Names:
|
|
Experimental: Zanubrutinib Medium Dose
Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks
|
Administered as specified in the treatment arm
Other Names:
|
|
Experimental: Placebo
Participants will receive placebo to match zanubrutinib for 72 weeks
|
Placebo to match zanubrutinib
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants with complete renal response
Time Frame: Week 49 Day 1
|
Week 49 Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants achieving complete renal response
Time Frame: Up to Week 73 Day 1
|
Up to Week 73 Day 1
|
|
|
Proportion of participants achieving partial renal response
Time Frame: Up to Week 73 Day 1
|
Up to Week 73 Day 1
|
|
|
Proportion of participants achieving overall renal response
Time Frame: Up to Week 73 Day 1
|
Up to Week 73 Day 1
|
|
|
Time to first complete renal response
Time Frame: Up to Week 73 Day 1
|
The time from the date of randomization to the date of the first complete renal response
|
Up to Week 73 Day 1
|
|
Time to first overall renal response
Time Frame: Up to Week 73 Day 1
|
The time from the date of randomization to the date of the first overall renal response
|
Up to Week 73 Day 1
|
|
Change in total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score
Time Frame: Baseline to Week 49 Day 1
|
SLEDAI-2K score is a systemic lupus erythematosus (SLE) activity index based on the presence of 24 features in 9 organ systems which ranges from 0 - 105, with higher scores indicating more severe features in participants in the past 30 days
|
Baseline to Week 49 Day 1
|
|
Area under plasma concentration time curve (AUC) of zanubrutinib
Time Frame: Week 1 Day 1 and Week 5 Day 1
|
Week 1 Day 1 and Week 5 Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Zhen Yao, MD, BeiGene
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Glomerulonephritis
- Lupus Erythematosus, Systemic
- Nephritis
- Lupus Nephritis
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Zanubrutinib
Other Study ID Numbers
Other Study ID Numbers
- BGB-3111-217
- CTR20202662 (Other Identifier: ChinaDrugTrials)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.